Biotech founders bring years of experience in scientific research, breakthrough discoveries and the potential to transform healthcare. The journey of the innovation from lab bench to market is long and costly: commercializing scientific discoveries into viable drugs can span 15 years with development costs reaching $1 billion or more, when accounting for failures. These extended timelines create a fundamental mismatch between academic achievement and investor expectations. While prestigious journals reward groundbreaking basic research, venture capitalists demand clear commercial pathways, de-risked assets, and quantifiable market opportunities. Research from Stanford University reveals that scientific founders often lack the know-how to navigate the complex stakeholder ecosystem required for successful commercialization. They excel at discovery, yet struggle with good manufacturing practices, FDA interactions, team recruitment, and investor relations—each representing potential fatal roadblocks on the path to market.

Translating the complexities of scientific innovation into value-generating assets is fundamental to bridging discovery with the funding needed for the transformation into real-world applications. 

Overcoming the scientific & technical complexity barrier

Biotech founders face a paradox: they must demonstrate scientific innovation and rigor while making complex technologies, scientific concepts and mechanisms of action accessible to non-specialist audiences. While a well-prepared pitch deck does not guarantee investment, a poorly prepared one can be fatal. A few common pitfalls that diminish the strength of a pitch deck are:

• Use of excessive technical jargon

• Unclear value proposition

• Focus on the “what” rather than the “why does it matter”

To create a sticky narrative that captures investor attention, messages containing context-specific terms need to be translated into widely accessible language, while maintaining accuracy. Incorporation of a few strategically selected specialized ‘hook’ terms can help build differentiation into narrative. It is critical, however, that these ‘hook’ terms are used in moderation and appropriately defined for the audience.

Framing the scientific discovery into an investment-worthy narrative

Biotech startups raised $28.1 billion in venture capital in 2024, with the median biotech venture round now hovering around $93-100 million. This continues the "megaround" trend, with fewer deals, larger checks, and higher barriers to entry. To surmount these barriers, founders must demonstrate that they meet a few key investor requirements – they have great people, great science, and differentiation. An effective narrative answers the following fundamental questions:

• What existing problem is your discovery addressing?

• Who are the users / beneficiaries of your discovery?

• What is your solution?

• Why is it better than the existing solutions addressing similar problems?

• What is your plan for implementing your solution?

• How do you measure success?

Instead of drowning investors in scientific journal articles and dense datasets, successful founders tell stories. They use analogies, metaphors, and visual aids to explain complex concepts without sacrificing accuracy. They focus on practical implications – for example, how science translates into tangible patient benefits, instead of getting lost in technical details. They also recognize that different stakeholders require different messaging. A regulatory consultancy's value proposition needs separate articulation for investors, clinicians, and patients, each tailored to that audience's rational and emotional needs while maintaining consistency.

Brilliant science does not guarantee business success. However, successful communication of brilliant science builds credible scientific narratives accessible to diverse audiences and demonstrates clear paths from discovery to commercial value. In turn, this strengthens stakeholder relationships, and secures funding required to convert brilliant science into real-world transformation.  

Previous article | Back to Blog Home